Physiological significance of endothelin: Its role in congestive heart failure

A. Clavell, A. Stingo, K. Margulies, Amir Lerman, D. Underwood, John C Jr. Burnett

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Endothelin (ET) is a endothelium-derived peptide with potent vasoconstrictor and growth-promoting actions. Although its physiological role remains unclear, recent studies report increased ET in various pathophysiological states, including congestive heart failure (CHF). The mechanisms contributing to increased ET in CHF probably include hemodynamic factors like increased atrial and venous pressures and reduced perfusion pressure and shear stress. Recent investigations also suggest that the kidney, lung, heart, and peripheral vasculature are sites of ET messenger RNA expression that may contribute to the elevation of ET in pathophysiological states. Recent studies have demonstrated that ET infusion to mimic pathophysiological levels has important biological actions, suggesting that ET may play an important role as a circulating hormone to maintain adequate perfusion during CHF. However, recent reports demonstrate that endogenous vasodilators like atrial natriuretic factor and endothelium-derived relaxing factor may attenuate ET actions in vivo. In conclusion, ET is a potent vasoconstricting and mitogenic peptide of endothelial origin that may participate in the adaptations to acute reductions in perfusion pressure in CHF. As this syndrome progresses, ET may contribute to the systemic vasoconstriction and cardiac vascular remodeling that characterize severe CHF. It is likely that therapeutic regimens that block or prevent the activation of ET or antagonize its actions may have a beneficial role in the treatment of heart failure.

Original languageEnglish (US)
JournalCirculation
Volume87
Issue number5 SUPPL. V
StatePublished - 1993

Fingerprint

Endothelins
Heart Failure
Perfusion
Pressure
Endothelium-Dependent Relaxing Factors
Peptides
Venous Pressure
Atrial Pressure
Atrial Natriuretic Factor
Vasoconstrictor Agents
Vasoconstriction
Treatment Failure
Vasodilator Agents
Endothelium
Hemodynamics
Hormones
Kidney
Lung
Messenger RNA

Keywords

  • blood pressure
  • endothelin
  • heart failure, congestive
  • vasoconstriction

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Clavell, A., Stingo, A., Margulies, K., Lerman, A., Underwood, D., & Burnett, J. C. J. (1993). Physiological significance of endothelin: Its role in congestive heart failure. Circulation, 87(5 SUPPL. V).

Physiological significance of endothelin : Its role in congestive heart failure. / Clavell, A.; Stingo, A.; Margulies, K.; Lerman, Amir; Underwood, D.; Burnett, John C Jr.

In: Circulation, Vol. 87, No. 5 SUPPL. V, 1993.

Research output: Contribution to journalArticle

Clavell, A, Stingo, A, Margulies, K, Lerman, A, Underwood, D & Burnett, JCJ 1993, 'Physiological significance of endothelin: Its role in congestive heart failure', Circulation, vol. 87, no. 5 SUPPL. V.
Clavell, A. ; Stingo, A. ; Margulies, K. ; Lerman, Amir ; Underwood, D. ; Burnett, John C Jr. / Physiological significance of endothelin : Its role in congestive heart failure. In: Circulation. 1993 ; Vol. 87, No. 5 SUPPL. V.
@article{c14360ba239e4e9eb56d7002e6423615,
title = "Physiological significance of endothelin: Its role in congestive heart failure",
abstract = "Endothelin (ET) is a endothelium-derived peptide with potent vasoconstrictor and growth-promoting actions. Although its physiological role remains unclear, recent studies report increased ET in various pathophysiological states, including congestive heart failure (CHF). The mechanisms contributing to increased ET in CHF probably include hemodynamic factors like increased atrial and venous pressures and reduced perfusion pressure and shear stress. Recent investigations also suggest that the kidney, lung, heart, and peripheral vasculature are sites of ET messenger RNA expression that may contribute to the elevation of ET in pathophysiological states. Recent studies have demonstrated that ET infusion to mimic pathophysiological levels has important biological actions, suggesting that ET may play an important role as a circulating hormone to maintain adequate perfusion during CHF. However, recent reports demonstrate that endogenous vasodilators like atrial natriuretic factor and endothelium-derived relaxing factor may attenuate ET actions in vivo. In conclusion, ET is a potent vasoconstricting and mitogenic peptide of endothelial origin that may participate in the adaptations to acute reductions in perfusion pressure in CHF. As this syndrome progresses, ET may contribute to the systemic vasoconstriction and cardiac vascular remodeling that characterize severe CHF. It is likely that therapeutic regimens that block or prevent the activation of ET or antagonize its actions may have a beneficial role in the treatment of heart failure.",
keywords = "blood pressure, endothelin, heart failure, congestive, vasoconstriction",
author = "A. Clavell and A. Stingo and K. Margulies and Amir Lerman and D. Underwood and Burnett, {John C Jr.}",
year = "1993",
language = "English (US)",
volume = "87",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "5 SUPPL. V",

}

TY - JOUR

T1 - Physiological significance of endothelin

T2 - Its role in congestive heart failure

AU - Clavell, A.

AU - Stingo, A.

AU - Margulies, K.

AU - Lerman, Amir

AU - Underwood, D.

AU - Burnett, John C Jr.

PY - 1993

Y1 - 1993

N2 - Endothelin (ET) is a endothelium-derived peptide with potent vasoconstrictor and growth-promoting actions. Although its physiological role remains unclear, recent studies report increased ET in various pathophysiological states, including congestive heart failure (CHF). The mechanisms contributing to increased ET in CHF probably include hemodynamic factors like increased atrial and venous pressures and reduced perfusion pressure and shear stress. Recent investigations also suggest that the kidney, lung, heart, and peripheral vasculature are sites of ET messenger RNA expression that may contribute to the elevation of ET in pathophysiological states. Recent studies have demonstrated that ET infusion to mimic pathophysiological levels has important biological actions, suggesting that ET may play an important role as a circulating hormone to maintain adequate perfusion during CHF. However, recent reports demonstrate that endogenous vasodilators like atrial natriuretic factor and endothelium-derived relaxing factor may attenuate ET actions in vivo. In conclusion, ET is a potent vasoconstricting and mitogenic peptide of endothelial origin that may participate in the adaptations to acute reductions in perfusion pressure in CHF. As this syndrome progresses, ET may contribute to the systemic vasoconstriction and cardiac vascular remodeling that characterize severe CHF. It is likely that therapeutic regimens that block or prevent the activation of ET or antagonize its actions may have a beneficial role in the treatment of heart failure.

AB - Endothelin (ET) is a endothelium-derived peptide with potent vasoconstrictor and growth-promoting actions. Although its physiological role remains unclear, recent studies report increased ET in various pathophysiological states, including congestive heart failure (CHF). The mechanisms contributing to increased ET in CHF probably include hemodynamic factors like increased atrial and venous pressures and reduced perfusion pressure and shear stress. Recent investigations also suggest that the kidney, lung, heart, and peripheral vasculature are sites of ET messenger RNA expression that may contribute to the elevation of ET in pathophysiological states. Recent studies have demonstrated that ET infusion to mimic pathophysiological levels has important biological actions, suggesting that ET may play an important role as a circulating hormone to maintain adequate perfusion during CHF. However, recent reports demonstrate that endogenous vasodilators like atrial natriuretic factor and endothelium-derived relaxing factor may attenuate ET actions in vivo. In conclusion, ET is a potent vasoconstricting and mitogenic peptide of endothelial origin that may participate in the adaptations to acute reductions in perfusion pressure in CHF. As this syndrome progresses, ET may contribute to the systemic vasoconstriction and cardiac vascular remodeling that characterize severe CHF. It is likely that therapeutic regimens that block or prevent the activation of ET or antagonize its actions may have a beneficial role in the treatment of heart failure.

KW - blood pressure

KW - endothelin

KW - heart failure, congestive

KW - vasoconstriction

UR - http://www.scopus.com/inward/record.url?scp=0027315746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027315746&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027315746

VL - 87

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 5 SUPPL. V

ER -